英菲格拉替尼的用法用量是怎样的?

Infigratinib is an oral FGFR selective inhibitor. In May 2021, the US FDA accelerated the approval of infigratinib. This approval was approved for the treatment of previously treated and unresectable locally advanced metastatic cholangiocarcinoma patients. In clinical treatment, infigratinib can significantly It prolongs the patient's survival period and has a very significant improvement effect on the patient's condition. It is a rare drug in recent years. However, since it is a drug, the daily dosage of Infigratinib affects the efficacy of Infigratinib. Let us take a look at the usage and dosage of Infigratinib.

What is the dosage of Infigratinib?

The recommended dosage of infigratinib will vary depending on the severity of the disease, but it is necessary to determine whether there is FGFR2 gene fusion or rearrangement before using this product. Infigratinib needs to be taken on an empty stomach, at least one hour before meals or 2 hours after meals. The recommended dose is 125 mg, taken orally once a day, with a treatment cycle of 28 days, with 21 consecutive days of medication and 7 days of drug withdrawal.

It should be noted that patients cannot crush Infigratinib during medication, let alone chew or dissolve Infigratinib. Patients need to swallow it whole. For patients with mild and moderate renal insufficiency, the recommended dose of Infigratinib is 100 mg. For patients with mild liver damage, the recommended dose of Infigratinib is 100 mg. For patients with moderate liver damage, the recommended dose of Infigratinib is 75 mg.